Debiopharm, an independent Swiss biopharmaceutical company based in Lausanne, seeks to carve a niche in the competitive oncology and infectious disease markets. Its business model focuses on in-licensing promising drug candidates from universities and smaller biotechs, aiming to add value through development. (The company is also partnering with AI-focused firms like VeriSIM Life.) Sandra von Meier, its head of business development, highlights the company’s exploration of DNA damage response pathways, with Debio 0123, a Wee1 kinase inhibitor, as a notable Phase I asset. Debiopharm also emphasizes its proprietary Multilink linker technology for antibody-drug conjugates, a field with potential to improve therapeutic outcomes.
We’ve lightly edited the responses for brevity.
Can you provide a broad overview of Debiopharm and its drug discovery and development strategy?Sandra von Me…